HUTCHMED Ltd (HCM) Form 6-K — Sep 24, 2026

HUTCHMED announced that new and updated data from its oncology pipeline will be presented at the ESMO Congress 2026 in Madrid, October 23-27, 2026. Two positive Phase III studies of the savolitinib plus osimertinib combination in EGFR-mutated NSCLC were selected for oral presentations: the global SAFFRON study in a Presidential Symposium and the China SANOVO study as a Proffered Paper. SAFFRON showed statistically significant PFS and OS improvement versus chemotherapy post-osimertinib, while SANOVO showed significant PFS benefit versus osimertinib monotherapy in treatment-naive patients.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.